Q3 2025 MannKind Corp Earnings Call Transcript

Nov 5, 2025 / 02:00 PM GMT

Release Date Price: €4.66 (-2.06%)

Transcript 10-Q8-K

Key Points

Positve

MannKind Corp (MNKD) delivered a record revenue quarter of $82 million, driven by strong performance from Tyvaso DPI.
The acquisition of SC Pharmaceuticals is expected to strengthen MannKind Corp's portfolio and enhance commercial scale.
Afrezza showed significant growth, with a 31% increase in new prescriptions and a 23% rise in net revenue year over year.
The company is advancing its pipeline with the acceptance of Fred's supplemental BLA for review and the submission of SNDA for the 406 autoinjector.
MannKind Corp is expanding its focus into cardio renal medicine with the addition of Firoix, addressing significant unmet needs in heart failure and CKD.

Negative

Despite revenue growth, MannKind Corp's GAAP net income decreased to $8 million from $11.6 million in the prior year.
The shift in focus to type 1 diabetes has led to a decline in units per script for Afrezza by about 15% year over year.
Vigo's contribution to revenue decreased by 19% compared to the prior year period.
The integration of SC Pharmaceuticals may present challenges, although initial reports suggest a smooth process.
There are concerns about the competitive landscape and pricing pressures, particularly with new competitors entering the market for similar products.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MNKD.OQ - MannKind Corp
Q3 2025 MannKind Corp Earnings Call
Nov 05, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Mankind Corporation 3rd quarter 2025 financial results earnings call.

As a reminder, this call is being recorded on November 5, 2025 and will be available for playback on the Mankind Corporation website shortly after the conclusion of this call and available for approximately 90 days.

This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from these expectations.

For further information on the company's risk factors, please see the form 10 for the quarterly period ended September 30th, 2025. The earnings release and the slides prepared for this presentation.

Joining us today for

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.